Market Overview:
The global indoleamine 2,3 dioxygenase 1 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of cancer, rising investments in R&D for novel therapies, and growing demand for targeted therapies. Based on type, the global indoleamine 2,3 dioxygenase 1 market is segmented into BMS-986205, Dcellvax, Epacadostat, F-001287 (pomalidomide), Galanal (larotrectinib), and others. Based on application, the market is segmented into aolpecia (head and neck cancer), cervical cancer (HPV-related cancers), gastric cancer (stomach cancer), glioma (brain tumor), and others. Geographically speaking North America dominates the global indoleamine 2 3 dioxygenase 1 market followed by Europe owing to better reimbursement scenario in these regions coupled with presence of major players operating in this space.
Product Definition:
Indoleamine 2,3 Dioxygenase 1 (IDO1) is an enzyme that catalyzes the oxidative cleavage of indoleamines. IDO1 is expressed in a variety of tissues, including the brain, placenta, and lymphoid cells. The expression of IDO1 by these cells leads to the degradation of tryptophan into kynurenine. Kynurenine can then be converted into a number of different metabolites that have important biological effects.
BMS-986205:
BMS-986205 is a selective inhibitor of IDO1. It has been studied in combination with Tumor Necrosis Factor (TNF) as a potential therapy for multiple myeloma and relapsed or refractory acute lymphoblastic leukemia in Phase II clinical trials. The drug has also shown efficacy against the model of Alzheimer’s disease, which is associated with Abeta peptides.
Dcellvax:
Dcellvax is a vaccine developed by Merck KGaA. It protects against dengue, Zika, and chikungunya viruses. The vaccine consists of an attenuated virus strain of the relevant virus and is designed to produce antibodies in the human body which can neutralize the infectious agent.
The product was approved by the FDA for sale in U.S.
Application Insights:
Indoleamine 2,3 dioxygenase 1 was found to be effective in the treatment of various cancers including aolpecia, cervical cancer, gastric cancer, glioma and others. The aolpecia segment held the largest share of over 25% in 2017. This can be attributed to increasing awareness about available treatment options along with rising incidences of this disease across the globe. In addition, growing research collaborations among key players for developing novel products are expected to drive market growth during the forecast period.
The gastric cancer segment is anticipated to witness lucrative growth during the forecast period owing to high incidence rates coupled with low mortality rates associated with this condition globally as well as locally available treatments options such as R&D investments by private companies.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing region over the forecast period. The presence of a large number of target disease populations and rising healthcare expenditure are some factors driving this regional market. In addition, increasing awareness about G2DOase treatment options and availability of effective drugs in emerging countries such as China, India, South Korea & Japan are anticipated to further boost growth during the forecast period.
The Asia Pacific was followed by North America in terms of market share with around 23% revenue share in 2017 due to higher R&D investments by pharmaceutical companies coupled with better access to healthcare facilities for patients diagnosed with indolamine 2,3 dioxygenase 1-associated diseases. Moreover, high prevalence rate for stomach cancer & gastrointestinal disorders is also one factor attributing towards larger market share held by this region.
Growth Factors:
- Increasing research and development activities by pharmaceutical and biotechnology companies for the treatment of various diseases with I2,3-DIO will drive the growth of this market.
- Growing demand for novel drugs that can target multiple pathways in cancer cells will fuel the growth of this market.
- Rising prevalence of cancer and other immune-mediated diseases will create a high demand for I2,3-DIO inhibitors in the coming years.
- increasing number of collaborations between pharmaceutical companies and academic institutions to develop novel therapies for various indications will propel the growth of this market during the forecast period.
- 3-DIO inhibitors is expected to spur market growth over the next few years
Scope Of The Report
Report Attributes
Report Details
Report Title
Indoleamine 2,3 Dioxygenase 1 Market Research Report
By Type
BMS-986205, Dcellvax, Epacadostat, F-001287, Galanal, Others
By Application
Aolpecia, Cervical Cancer, Gastric Cancer, Glioma, Others
By Companies
BirchBioMed Inc, Bristol-Myers Squibb Company, Ensemble Therapeutics Corp, F. Hoffmann-La Roche Ltd, Genentech Inc, Globavir Biosciences Inc, Incyte Corp, IO Biotech ApS, Kyowa Hakko Kirin, Netherlands Translational Research Center BV, NewLink Genetics Corp, Pfizer Inc, Redx Pharma Plc, Regen BioPharma Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Indoleamine 2,3 Dioxygenase 1 Market Report Segments:
The global Indoleamine 2,3 Dioxygenase 1 market is segmented on the basis of:
Types
BMS-986205, Dcellvax, Epacadostat, F-001287, Galanal, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Aolpecia, Cervical Cancer, Gastric Cancer, Glioma, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BirchBioMed Inc
- Bristol-Myers Squibb Company
- Ensemble Therapeutics Corp
- F. Hoffmann-La Roche Ltd
- Genentech Inc
- Globavir Biosciences Inc
- Incyte Corp
- IO Biotech ApS
- Kyowa Hakko Kirin
- Netherlands Translational Research Center BV
- NewLink Genetics Corp
- Pfizer Inc
- Redx Pharma Plc
- Regen BioPharma Inc
Highlights of The Indoleamine 2,3 Dioxygenase 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BMS-986205
- Dcellvax
- Epacadostat
- F-001287
- Galanal
- Others
- By Application:
- Aolpecia
- Cervical Cancer
- Gastric Cancer
- Glioma
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Indoleamine 2,3 Dioxygenase 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Indoleamine 2,3 dioxygenase 1 is an enzyme that catalyzes the conversion of indoleamines to 3-hydroxyindoles. This reaction is important in the biosynthesis of serotonin and melatonin.
Some of the major players in the indoleamine 2,3 dioxygenase 1 market are BirchBioMed Inc, Bristol-Myers Squibb Company, Ensemble Therapeutics Corp, F. Hoffmann-La Roche Ltd, Genentech Inc, Globavir Biosciences Inc, Incyte Corp, IO Biotech ApS, Kyowa Hakko Kirin, Netherlands Translational Research Center BV, NewLink Genetics Corp, Pfizer Inc, Redx Pharma Plc, Regen BioPharma Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Indoleamine 2,3 Dioxygenase 1 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Indoleamine 2,3 Dioxygenase 1 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Indoleamine 2,3 Dioxygenase 1 Market - Supply Chain
4.5. Global Indoleamine 2,3 Dioxygenase 1 Market Forecast
4.5.1. Indoleamine 2,3 Dioxygenase 1 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Indoleamine 2,3 Dioxygenase 1 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Indoleamine 2,3 Dioxygenase 1 Market Absolute $ Opportunity
5. Global Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Type
5.3.1. BMS-986205
5.3.2. Dcellvax
5.3.3. Epacadostat
5.3.4. F-001287
5.3.5. Galanal
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Application
6.3.1. Aolpecia
6.3.2. Cervical Cancer
6.3.3. Gastric Cancer
6.3.4. Glioma
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Indoleamine 2,3 Dioxygenase 1 Demand Share Forecast, 2019-2029
9. North America Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Application
9.4.1. Aolpecia
9.4.2. Cervical Cancer
9.4.3. Gastric Cancer
9.4.4. Glioma
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Type
9.7.1. BMS-986205
9.7.2. Dcellvax
9.7.3. Epacadostat
9.7.4. F-001287
9.7.5. Galanal
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Indoleamine 2,3 Dioxygenase 1 Demand Share Forecast, 2019-2029
10. Latin America Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Application
10.4.1. Aolpecia
10.4.2. Cervical Cancer
10.4.3. Gastric Cancer
10.4.4. Glioma
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Type
10.7.1. BMS-986205
10.7.2. Dcellvax
10.7.3. Epacadostat
10.7.4. F-001287
10.7.5. Galanal
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Indoleamine 2,3 Dioxygenase 1 Demand Share Forecast, 2019-2029
11. Europe Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Application
11.4.1. Aolpecia
11.4.2. Cervical Cancer
11.4.3. Gastric Cancer
11.4.4. Glioma
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Type
11.7.1. BMS-986205
11.7.2. Dcellvax
11.7.3. Epacadostat
11.7.4. F-001287
11.7.5. alanal
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Indoleamine 2,3 Dioxygenase 1 Demand Share, 2019-2029
12. Asia Pacific Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Application
12.4.1. Aolpecia
12.4.2. Cervical Cancer
12.4.3. Gastric Cancer
12.4.4. Glioma
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Type
12.7.1. BMS-986205
12.7.2. Dcellvax
12.7.3. Epacadostat
12.7.4. F-001287
12.7.5. Galanal
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Indoleamine 2,3 Dioxygenase 1 Demand Share, 2019-2029
13. Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Application
13.4.1. Aolpecia
13.4.2. Cervical Cancer
13.4.3. Gastric Cancer
13.4.4. Glioma
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Market Size and Volume Forecast by Type
13.7.1. BMS-986205
13.7.2. Dcellvax
13.7.3. Epacadostat
13.7.4. F-001287
13.7.5. Galanal
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Indoleamine 2,3 Dioxygenase 1 Market: Market Share Analysis
14.2. Indoleamine 2,3 Dioxygenase 1 Distributors and Customers
14.3. Indoleamine 2,3 Dioxygenase 1 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. BirchBioMed Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bristol-Myers Squibb Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Ensemble Therapeutics Corp
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. F. Hoffmann-La Roche Ltd
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Genentech Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Globavir Biosciences Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Incyte Corp
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. IO Biotech ApS
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Kyowa Hakko Kirin
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Netherlands Translational Research Center BV
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. NewLink Genetics Corp
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Pfizer Inc
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Redx Pharma Plc
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Regen BioPharma Inc
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
